Phase I dose-escalating study of raltitrexed ('Tomudex') and cisplatin in metastatic non-small cell lung cancer (Q33341951)

25 July 2017

title

Phase I dose-escalating study of raltitrexed ('Tomudex') and cisplatin in metastatic non-small cell lung cancer (English)

1 reference

25 July 2017

1 reference

Manegold C

1

1 reference

25 July 2017

Buchholz E

2

1 reference

25 July 2017

Kloeppel R

3

1 reference

25 July 2017

Kreisel C

4

1 reference

25 July 2017

Smith M

5

1 reference

25 July 2017

publication date

1 May 2002

1 reference

25 July 2017

1 reference

25 July 2017

volume

36

1 reference

25 July 2017

issue

2

1 reference

25 July 2017

page(s)

183-189

1 reference

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

'Tomudex' (ZD1694): A novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Revisions in the International System for Staging Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900491-3

7 January 2021

10.1016/S0169-5002(01)00491-3

Identifiers

DOI

1 reference

25 July 2017

1 reference